Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Menkowitz

Orthopaedic Surgery of the Spine Shrewsbury, NJ Medical Doctor

NPI 1710179114 CMS profile 213235

1131 Broad St, Suite 201, Shrewsbury, NJ 07702

Open in the dashboard

General payments

$13,407

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Menkowitz of Shrewsbury, NJ is reported in the CMS Open Payments database as having received $13,407 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $584 10
2024 General $5,153 10
2023 General $1,355 14
2022 General $551 12
2021 General $1,222 13
2020 General $1,643 15
2019 General $2,899 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Menkowitz
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Marc Menkowitz were reported at $584. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Marc Menkowitz Orthopaedic Surgery of the Spine median Middle half National median
2019 $2,899 $2,106 $337–$18,608 $163
2020 $1,643 $1,213 $156–$15,082 $114
2021 $1,222 $1,834 $271–$15,617 $132
2022 $551 $2,015 $320–$17,036 $149
2023 $1,355 $1,925 $336–$14,599 $160
2024 $5,153 $2,110 $341–$12,483 $164
2025 $584 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $8,030 13 payments
  2. NuVasive, Inc. $1,042 17 payments
  3. Integrity Implants Inc. $1,008 10 payments
  4. Addivation Medical LLC $1,000 1 payment
  5. Alphatec Spine, Inc $602 6 payments
  6. Nevro Corp. $440 20 payments
  7. Abbott Laboratories $249 11 payments
  8. OsteoCentric Technologies, Inc. $156 1 payment
  9. Biocomposites Inc $140 1 payment
  10. Intrinsic Therapeutics $127 1 payment
  11. Other $615 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,725 2 payments
  2. Food and Beverage $3,984 94 payments
  3. Travel and Lodging $3,698 7 payments
Products named General payments · program years 2019–2025
  1. Excelsius - GPS $2,190 5 payments
  2. CREO $905 2 payments
  3. FlareHawk $826 5 payments
  4. Xvision $600 5 payments
  5. Other - Miscellaneous $316 3 payments
  6. Senza Spinal Cord Stimulation System $309 15 payments
  7. XLIF $242 3 payments
  8. AMP $239 1 payment
  9. OsteoCentric 4.0 x 130mm LOCKING BONE SCREW FASTENER ST $156 1 payment
  10. Pulse $153 1 payment
  11. Other $1,813 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$147,492

Of which drugs: $495

Medicare patients

310

Average age 75

Services billed

1,642

184 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 34%
Osteoporosis 24%
COPD 20%
Atrial fibrillation 19%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 16 29 $166

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record